RT Journal Article
SR Electronic
T1 Metabolic markers distinguish COVID-19 from other intensive care patients and show potential to stratify for disease risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.13.21249645
DO 10.1101/2021.01.13.21249645
A1 Schmelter, Franziska
A1 Foeh, Bandik
A1 Mallagaray, Alvaro
A1 Rahmoeller, Johann
A1 Ehlers, Marc
A1 Lehrian, Selina
A1 Kopylow, Vera von
A1 Künsting, Inga
A1 Lixenfeld, Anne Sophie
A1 Martin, Emily
A1 Ragab, Mohab
A1 Borsche, Max
A1 Balck, Alexander
A1 Vollstedt, Eva Juliane
A1 Meyer-Saraei, Roza
A1 Kreutzmann, Fabian
A1 Eitel, Ingo
A1 Taube, Stefan
A1 Klein, Christine
A1 Katalinic, Alexander
A1 Rupp, Jan
A1 Jantzen, Eckard
A1 Graf, Tobias
A1 Sina, Christian
A1 Günther, Ulrich L
YR 2021
UL http://medrxiv.org/content/early/2021/01/16/2021.01.13.21249645.abstract
AB Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus. there is increasing interest in metabolic and lipoprotein signatures of the disease and early analyses have demonstrated metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether these are specific for COVID-19 or a general marker of critical illness. To answer this question, we have analyzed 276 serum samples from 92 individuals using NMR metabolomics, including longitudinally collected samples from 5 COVID-19 and 11 cardiogenic shock intensive care patients, 18 SARS-CoV-2 antibody-positive individuals, and 58 healthy controls.COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared to healthy controls. Specifically, VLDL parameters, IDL particles, large-sized LDL particles, and the ApoB100/ApoA1 ratio were significantly increased, whereas HDL fractions were decreased. Moreover, a similarly perturbed profile was apparent, even when compared to other ICU patients suffering from cardiogenic shock, highlighting the impact of COVID-19 especially on lipid metabolism and energy status. COVID-19 patients were separated with an AUROC of 1.0 when compared to both healthy controls and cardiogenic shock patients. Anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared to age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized LDL and HDL subfractions. Our data suggest that NMR metabolic profiles are suitable for COVID-19 patient stratification and post-treatment monitoring.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo clinical trial is involvedFunding StatementBF and MR are funded by the DFG, IRTG1911 program; CS is Fresenius Kabi endowed Professor for Nutritional Medicine. CS received research funding from Fresenius Kabi GmbH. FS and EJ are employees of GALAB GmbH, Hamburg. CK is funded by the DFG (Cluster of Excellence 2167 and FOR 2488).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval wa sgranted by the corresponding ethics committee (LUERIC-MICROBIOME Nr. 19-019 and 19-019 A, University of Luebeck)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur ethics does not allow to share the data without signing an agreement. Parties interested can contact the corresponding author to obtain access to this data.